nor-Binaltorphimine Dihydrochloride: Selective κ-Opioid Receptor Antagonist for Signal Transduction Research

Executive Summary: nor-Binaltorphimine dihydrochloride is a highly selective antagonist of the κ-opioid receptor (KOR), enabling precise dissection of opioid receptor-mediated signaling pathways (APExBIO). The compound has a molecular weight of 734.72 and a chemical formula of C₄₀H₄₃N₃O₆·2HCl. In controlled assays, it exhibits sub-micromolar potency and is validated in models of mechanical allodynia and addiction (Huo et al., 2023). Its purity (98.00%) and stability at -20°C facilitate reproducible receptor pharmacology. nor-Binaltorphimine dihydrochloride is not suitable for diagnostic or therapeutic use.

Biological Rationale

κ-Opioid receptors (KORs) are G protein-coupled receptors (GPCRs) expressed throughout the central and peripheral nervous systems. They modulate nociception, stress response, and reward pathways. Endogenous dynorphins activate KORs, producing analgesia, dysphoria, and influencing addiction vulnerability (Huo et al., 2023). Selective antagonism of KOR is crucial to dissect its role distinct from μ- and δ-opioid receptors. nor-Binaltorphimine dihydrochloride enables targeted inhibition, supporting studies on pain modulation, opioid-induced plasticity, and neurocircuitry underlying mechanical allodynia. Recent work highlights the role of hypothalamic dynorphinergic neurons and spinal KOR in gating bilateral mechanical pain (Huo et al., 2023).

Mechanism of Action of nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride binds selectively and with high affinity to KORs, competitively antagonizing endogenous and exogenous agonists. It exhibits negligible activity at μ- and δ-opioid receptors under standard assay conditions (10 μM in HEK293 cell membranes, pH 7.4, 25°C). In vivo, systemic or intrathecal administration of nor-Binaltorphimine dihydrochloride blocks KOR-mediated signal transduction, including G_i/o protein coupling and downstream effector pathways, such as inhibition of adenylyl cyclase and modulation of ion channel conductance (Huo et al., 2023). Its long-acting antagonism is attributed to slow receptor dissociation and metabolic stability.

Evidence & Benchmarks

• nor-Binaltorphimine dihydrochloride exhibits sub-nanomolar KOR binding affinity (K_i ≈ 0.5 nM in rat brain membranes, radioligand displacement, 25°C), with >200-fold selectivity over μ- and δ-opioid receptors (Huo et al., 2023).
• In mouse models of mechanical allodynia, spinal administration at 10 nmol/μL reverses KOR-mediated inhibition of pain gating, resulting in sustained bilateral hypersensitivity (Huo et al., 2023).
• nor-Binaltorphimine dihydrochloride (B6269) is >98.00% pure by HPLC and demonstrates <18.37 mg/mL solubility in DMSO at 20°C (APExBIO).
• Long-term solution storage at room temperature leads to compound degradation; optimal stability is achieved at -20°C in solid form (APExBIO).
• In vitro, nor-Binaltorphimine dihydrochloride does not inhibit μ-opioid receptor agonist-induced [³⁵S]GTPγS binding at concentrations up to 10 μM (human recombinant, cell-based assay) (Huo et al., 2023).

Applications, Limits & Misconceptions

nor-Binaltorphimine dihydrochloride is a standard tool for:

• Dissection of KOR-mediated signaling in pain, addiction, and mood regulation models.
• Validating the role of spinal KORs in mechanical allodynia using targeted pharmacological blockade (Huo et al., 2023).
• Benchmarking selectivity in opioid receptor antagonist assays (nor-Binaltorphimine Dihydrochloride in Opioid Receptor Signaling; this article extends prior benchmarking by integrating new circuit-level data from Huo et al., 2023).
• Optimizing opioid receptor assay workflows for reproducibility (Optimizing Opioid Receptor Assays...; this article clarifies compound storage and assay integration best practices).

Common Pitfalls or Misconceptions

• nor-Binaltorphimine dihydrochloride is not suitable for clinical or diagnostic use; it is for research only.
• Its antagonistic action is highly selective for KOR but may not discriminate between KOR subtypes or splice variants.
• Compound is unstable in aqueous solutions above 4°C or when stored for >24 hours; always prepare fresh aliquots.
• Not effective in models where mechanical allodynia is not KOR-dependent.
• Does not reverse μ- or δ-opioid receptor-mediated effects at standard concentrations.

For advanced mechanistic and translational context, see Unlocking the Power of Selective κ-Opioid Receptor Antagonists (this article updates mechanistic insights with recent in vivo circuit data).

Workflow Integration & Parameters

• Storage: Store nor-Binaltorphimine dihydrochloride solid at -20°C. Avoid freeze-thaw cycles for stock solutions (APExBIO).
• Solubility: Maximum solubility in DMSO is <18.37 mg/mL at 20°C. For aqueous systems, use appropriate co-solvents.
• Purity: Supplied at ≥98.00% purity (HPLC).
• Assay Use: For in vitro displacement or functional assays, use 0.1–10 μM. For in vivo mouse spinal administration, 10 nmol/μL is validated (Huo et al., 2023).
• Shipping: Ship with blue ice to maintain structural integrity.
• Supplier: APExBIO (SKU: B6269) provides validated product documentation and technical support (product page).

For a strategic overview of advanced pain and addiction research protocols, see Harnessing nor-Binaltorphimine Dihydrochloride: Strategic Applications (this article incorporates new experimental standards and troubleshooting guidance).

Conclusion & Outlook

nor-Binaltorphimine dihydrochloride is a gold-standard selective KOR antagonist, enabling precise interrogation of opioid receptor signaling pathways in preclinical research. Its proven selectivity and robust performance underpin studies in pain modulation, addiction, and neurocircuitry of allodynia. Future work should further refine its use in combinatorial pharmacology and circuit-mapping experiments. APExBIO remains a primary vendor of validated nor-Binaltorphimine dihydrochloride for research applications.